Tenosynovitis
Conditions
Interventions
Injection will consist of 20mg kenacort, 5mg kenacort or 20mg depomedrol. Each injection will be combined with 5mg lidocaine. For each type of steroid, 1 cc will be injected per finger.
Sponsors
Jeroen Bosch Hospital,
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - One or more trigger fingers - Grade 1-3 trigger finger (according to classification by Quinnell) - Participation is voluntary and with informed consent
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Aged <18 - Congenital trigger finger - Mentally disabled persons - Grade 4 trigger finger (according to classification by Quinell) - Allergy for corticosteroids - Previous surgical release for triggering - Previous injection therapy - History of surgical intervention in the same digit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Objective: The primary outcome to be compared is the success rate of Kenalog-40, Kenalog-10 and Depo-Medrol 40 mg/ml in the treatment of a trigger finger. Success rate is defined as no persistent or recurrence of a trigger finger after injection (maximum three injections). We hypothesize that Depo-Medrol 40 mg/ml has the highest success rate (considering rate of persistence, recurrence and amount of injections) and Kenalog-10 is lowest success rate. We expect less difference between Depo-Medrol 40 mg/ml and Kenalog-40 than between Kenalog-40 and Kenalog-10. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Difference in patient reported outcomes (MHOQ and NRS scores) - Difference in ROM before and two months after injection - Difference in costs - Difference in number and kind of complications - Difference in quinnell primary result after 1, 2 or 3 injection - Difference in after how many injections(1,2 or 3) the treatment is considered a success in the three different research arms. | — |
Contacts
Public ContactCatherine van den Berg
jeroen bosch ziekenhuis
Outcome results
None listed